Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

1H4R

Crystal Structure of the FERM domain of Merlin, the Neurofibromatosis 2 Tumor Suppressor Protein.

Summary for 1H4R
Entry DOI10.2210/pdb1h4r/pdb
DescriptorMERLIN, SULFATE ION (3 entities in total)
Functional Keywordsferm, neurofibromatosis, nf2, structural protein, cytoskeleton, anti-oncogene
Biological sourceHOMO SAPIENS (HUMAN)
Total number of polymer chains2
Total formula weight74552.07
Authors
Cooper, D.R.,Kang, B.S.,Sheffield, P.,Devedjiev, Y.,Derewenda, Z.S. (deposition date: 2001-05-14, release date: 2002-01-16, Last modification date: 2023-12-13)
Primary citationKang, B.S.,Cooper, D.R.,Devedjiev, Y.,Derewenda, U.,Derewenda, Z.S.
The Structure of the Ferm Domain of Merlin, the Neurofibromatosis Type 2 Gene Product.
Acta Crystallogr.,Sect.D, 58:381-, 2002
Cited by
PubMed Abstract: Neurofibromatosis type 2 is an autosomal dominant disorder characterized by central nervous system tumors. The cause of the disease has been traced to mutations in the gene coding for a protein that is alternately called merlin or schwannomin and is a member of the ERM family (ezrin, radixin and moesin). The ERM proteins link the cytoskeleton to the cell membrane either directly through integral membrane proteins or indirectly through membrane-associated proteins. In this paper, the expression, purification, crystallization and crystal structure of the N-terminal domain of merlin are described. The crystals exhibit the symmetry of space group P2(1)2(1)2(1), with two molecules in the asymmetric unit. The recorded diffraction pattern extends to 1.8A resolution. The structure was solved by the molecular-replacement method and the model was refined to a conventional R value of 19.3% (R(free) = 22.7%). The N-terminal domain of merlin closely resembles those described for the corresponding domains in moesin and radixin and exhibits a cloverleaf architecture with three distinct subdomains. The structure allows a better rationalization of the impact of selected disease-causing mutations on the integrity of the protein.
PubMed: 11856822
DOI: 10.1107/S0907444901021175
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.8 Å)
Structure validation

227933

PDB entries from 2024-11-27

PDB statisticsPDBj update infoContact PDBjnumon